methyclothiazide

Trade name: enduron

Small moleculeapproved

Approved

Oct 21, 1960

Methyclothiazide, a diuretic-antihypertensive agent, is a member of the benzothiadiazine (thiazide) class of drugs. Methyclothiazide has a per mg natriuretic activity approximately 100 times that of the prototype thiazide, chlorothiazide. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic/natriuretic effects. Like other benzothiadiazines, methyclothiazide also has antihypertensive properties, and may be used for this purpose either alone or to enhance the antihypertensive action of other drugs. Methyclothiazide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis. As a diuretic, methyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like methyclothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of methyclothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. Methyclothiazide is used in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Also used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 11 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1960s

  1. Oct 21, 1960

    AbbVie — Earliest FDA Approval

  2. Oct 21, 1960

    AbbVie — NDA Secondary Org

  3. Oct 21, 1960

    AbbVie — NDA Organization

  4. Aug 1, 1961

    Abbott — Marketing Organization

  5. Aug 1, 1961

    Abbott — NDA Secondary Org

1970s

  1. Sep 30, 1975

    Medpointe — NDA Secondary Org

1980s

  1. Jun 3, 1982

    Ivax — Marketing Organization

  2. Aug 17, 1982

    Mylan — Marketing Organization

  3. Aug 17, 1982

    PHARMOBEDIENT — Marketing Organization

  4. Sep 6, 1984

    Watson Pharmaceuticals — Marketing Organization

  5. Feb 12, 1986

    Par Pharmaceuticals — Marketing Organization

  6. Aug 18, 1988

    Fosun — Marketing Organization

  7. Aug 18, 1988

    Chartwell Pharmaceuticals — Marketing Organization

Indications

Mechanism of action

Combination products

Approval history

  • approvedOct 21, 1960

Chemistry & pharmacology

Loading structure…

SMILES

CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O
Mol. weight
360.237 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • aquatensen
  • aquatensen
  • enduron
  • enduron
  • enduron
  • enduron
  • methychlothiazide
  • methychlothiazide
  • methychlothiazide
  • methychlothiazide
  • methychlothiazide
  • methychlothiazide
  • methyclothiazid
  • methyclothiazide
  • methyclothiazide
  • methyclothiazide
  • methyclothiazide
  • methyclothiazide
  • methyclothiazide
  • methyclothiazide
  • methylclothiazide
  • methylclothiazide

Organizations

Marketing (13)

OrganizationOrg typeRelationshipDate
AbbVieFor profitNDA2Oct 21, 1960
AbbVieFor profitNDAOct 21, 1960
AbbottFor profitMKTGAug 1, 1961
AbbottFor profitNDA2Aug 1, 1961
Chartwell PharmaceuticalsFor profitMKTGAug 18, 1988
FosunFor profitMKTGAug 18, 1988
IvaxFor profitMKTGJun 3, 1982
MedpointeFor profitNDA2Sep 30, 1975
MylanFor profitMKTGAug 17, 1982
PHARMOBEDIENTFor profitMKTGAug 17, 1982
Par PharmaceuticalsFor profitMKTGFeb 12, 1986
Upsher-Smith LaboratoriesFor profitMKTG
Watson PharmaceuticalsFor profitMKTGSep 6, 1984